Jim Cramer Blog

Lumera (NASDAQ:LMRA - News) shares rose 38% after the Bothell, Wash.-based nanotechnology company announced that Harvard Medical School researchers are now building discovery and diagnostics methods with Lumera's ProteomicProcessor biosensor. Lumera said Harvard has served as a beta site for Lumera's biosensor platform since mid-2006. The Harvard collaboration is focused on integrating their Nucleic Acid Programmable Protein Array technology with Lumera's ProteomicProcessor, the company said. "We now have a solid foundation on which to begin our development efforts," said Dr. Joshua LaBaer, director of the Harvard Institute of Proteomics, in a statement. "Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research."